1. A method of creating a logical profile for physical devices in a system to interface with a monitoring system, the method comprising:
selecting a profile identity;
selecting a plurality of physical devices from the system, the physical devices including an output or an input;
defining an input or output for at least one of the plurality of selected physical devices as a tag; and
wherein the plurality of selected physical devices are represented to the monitoring system by the profile identity and the at least one tag of the selected physical devices.
2. The method of claim 1, wherein the tag is assigned to any physical device type that has the defined input or output.
3. The method of claim 1, wherein the physical devices include power monitoring devices and power control devices.
4. The method of claim 1, wherein the selected plurality of physical devices include a controller and slave devices coupled to the controller.
5. The method of claim 1, wherein the logical profile is matched to additional devices on the system to represent the additional devices.
6. The method of claim 1, further comprising creating a functional block for the logical profile, the functional block including a plurality of tags, the functional block applied to all physical devices having inputs or outputs defined by the plurality of tags, the functional blocks defining the addresses of the inputs or outputs with an offset for each device represented by the function block.
7. The method of claim 1, wherein the tag includes real time data, an alarm signal or control signals.
8. The method of claim 1, wherein the plurality of selected physical devices includes a processing device calculating data received from another one of the plurality of selected physical devices and the tag defines the calculated data.
9. A monitoring system comprising:
a plurality of physical devices having inputs or outputs;
a master controller coupled to the plurality of physical devices; and
a monitoring system on the master controller, the monitoring system interfacing with the plurality of devices via a logical profile representing a selected number of physical devices from the plurality of physical devices, the logical profile including at least one tag defining an input or output for one of the selected physical devices.
10. The system of claim 9, wherein the tag is assigned to any physical device type that has the defined input or output.
11. The system of claim 9, wherein the physical devices include power monitoring devices and power control devices.
12. The system of claim 9, wherein the selected plurality of physical devices includes a controller and slave devices coupled to the controller.
13. The system of claim 9, wherein the logical profile is matched to additional devices on the system to represent the additional devices.
14. The system of claim 9, wherein the logical profile includes a functional block including a plurality of tags, the functional block applied to all physical devices having inputs or outputs defined by the plurality of tags, the functional blocks defining the addresses of the inputs or outputs with an offset for each device represented by the function block.
15. The system of claim 9, wherein the tag includes real time data, an alarm signal or control signals.
16. The system of claim 9, further comprising a network coupled to the master controller and the plurality of physical devices.
17. The system of claim 9, wherein the plurality of selected physical devices includes a processing device calculating data received from another one of the plurality of selected physical devices and the tag defines the calculated data.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical formulation comprising an immediate release component and an extended release component wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval.
2. A pharmaceutical formulation according to claim 1, wherein APAP is present in said pharmaceutical formation at a dosage strength ranging from about 325 to about 1300 mg in one or more unit dosage forms.
3. A pharmaceutical formulation according to claim 1, wherein APAP is present in the formulation at a dosage strength comprising 325, 500, or 650 mg.
4. A pharmaceutical formulation according to claim 1, wherein at least one active pharmaceutical ingredient is added to at least one of said immediate release component or said extended release component or both.
5. A pharmaceutical formulation according to claim 4, wherein the at least one active pharmaceutical ingredient is selected from the group consisting of an opioid or opioid-like compound, a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-II (COX-2) inhibitor, a glycine receptor antagonist, an antitussive, an expectorant, a decongestant, an antihistamine and mixtures thereof.
6. A pharmaceutical formulation according to claim 5, wherein said active pharmaceutical ingredient is an opioid or opioid-like compound.
7. A pharmaceutical formulation according to claim 6, wherein said opioid or opioid-like compound is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, and salts of any of the foregoing.
8. A pharmaceutical formulation according to claim 7, wherein said opioid or opioid-like compounds is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, or salts thereof, and mixtures thereof.
9. A pharmaceutical formulation according to claim 8, wherein said active pharmaceutical ingredient is a propoxyphene salt.
10. A pharmaceutical formulation according to claim 9, wherein the propoxyphene salt is selected from the group consisting of propoxyphene napsylate and propoxyphene hydrochloride.
11. A pharmaceutical formulation according to claim 9, wherein the propoxyphene salt is present in the immediate release and extended release components as a weight ratio comprising 50%IR:50%ER, 45%IR:55% ER, or 40%IR:60%ER.
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. A pharmaceutical formulation according to claim 1, wherein the immediate release component comprises APAP, at least one disintegrant, and, optionally, one or more binders.
21. (canceled)
22. (canceled)
23. (canceled)
24. A pharmaceutical formulation according to claim 1, wherein the extended release component at least one controlled release matrix polymer, and, optionally, one or more APIs.
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. (canceled)
48. (canceled)
49. (canceled)
50. (canceled)
51. (canceled)
52. A pharmaceutical formulation in unit dosage form comprising per dosage unit an amount of APAP within a range from about 325 to about 1300 mg of a composition comprising an immediate release component and an extended release component wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval, and wherein said formulation in unit dosage form being adapted for oral administration.
53. (canceled)
54. (canceled)
55. A pharmaceutical formulation comprising a first active ingredient which is APAP and an optional second active ingredient selected from the group consisting of one or more opiod or opiod-like compound wherein, when said formulation is administered to a subject in a single dose and at a total dosage strength of 1300 mg APAP under fasting conditions, the maximum plasma concentration (Cmax) of the APAP following administration is in the range from about 5.89_ugmL to about 9.52_ugmL.
56. (canceled)
57. (canceled)
58. (canceled)
59. (canceled)
60. (canceled)
61. (canceled)
62. (canceled)
63. (canceled)
64. A pharmaceutical formulation comprising a blend of (a) an immediate release component comprising acetaminophen, an optional water soluble binder, and at least one disintegrant; and (b) an extended release component comprising at least one controlled release matrix polymer, and one or more optional fillers, and one or more optional wicking agents.
65. (canceled)
66. (canceled)
67. (canceled)
68. (canceled)
69. (canceled)
70. (canceled)
71. (canceled)
72. (canceled)
73. (canceled)
74. (canceled)
75. (canceled)
76. (canceled)
77. (canceled)
78. (canceled)
79. (canceled)
80. (canceled)
81. (canceled)
82. (canceled)
83. (canceled)
84. (canceled)
85. (canceled)
86. (canceled)
87. A pharmaceutical formulation comprising a blend of an immediate release component comprising APAP and an extended release component comprising optional APAP wherein when said formulation is administered to a subject for the treatment of pain for at least 8 hours, providing said formulation is not in the form of a bi-layer tablet.
88. (canceled)
89. (canceled)
90. (canceled)
91. (canceled)
92. (canceled)
93. A method of treating pain in a subject in need of such treatment comprising administering a pharmaceutically effective amount of a pharmaceutical formulation of claim 1.
94. A method of treating pain and a disease state resulting elevated histamine levels in a subject in need of such treatment comprising administering a pharmaceutically effective amount of a pharmaceutical formulation comprising an immediate release component, an extended release component, APAP, and an antihistimine wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval.
95. A method of treating pain and symptoms of respiratory illness in a subject in need of such treatment comprising administering a pharmaceutically effective amount of a pharmaceutical formulation comprising an immediate release component, an extended release component, APAP and one or more optional decongestants, one or more optional antitussives, and one or more expectorants wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval.
96. (canceled)